This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AKAO Achaogen (AKAO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Achaogen Stock (NASDAQ:AKAO) 30 days 90 days 365 days Advanced Chart Get Achaogen alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.11▼$0.1152-Week Range N/AVolumeN/AAverage Volume3.34 million shsMarket Capitalization$7.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. Read More Receive AKAO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achaogen and its competitors with MarketBeat's FREE daily newsletter. Email Address AKAO Stock News HeadlinesTriangle execs armed with $70M seek next big idea in life sciencesNovember 19, 2024 | bizjournals.comHarry R Weller's Net WorthSeptember 13, 2024 | benzinga.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 23 at 2:00 AM | Porter & Company (Ad)Ravi Viswanathan's Net WorthFebruary 21, 2024 | benzinga.comCOP28: Climate mums make themselves heard in halls of powerDecember 28, 2023 | bbc.comBAKAOQ Historical DataOctober 25, 2023 | investing.comSepterna Strengthens Leadership Team to Advance Novel Small Molecule GPCR Medicines - Yahoo FinanceJuly 28, 2022 | finance.yahoo.comAn N.J. medical expert warns of the rise of superbugs | Opinion - NJ.comJune 13, 2022 | nj.comNSee More Headlines AKAO Stock Analysis - Frequently Asked Questions How were Achaogen's earnings last quarter? Achaogen Inc (NASDAQ:AKAO) released its quarterly earnings results on Monday, August, 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.92) by $0.19. The biopharmaceutical company earned $2.56 million during the quarter, compared to analysts' expectations of $1.49 million. Achaogen had a negative trailing twelve-month return on equity of 357.49% and a negative net margin of 2,136.94%. What other stocks do shareholders of Achaogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Achaogen investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC) and Ciena (CIEN). Company Calendar Last Earnings8/06/2018Today8/23/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AKAO CIK1301501 Webwww.achaogen.com Phone650-800-3636FaxN/AEmployees206Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$186.51 million Net Margins-2,136.94% Pretax MarginN/A Return on Equity-357.49% Return on Assets-127.68% Debt Debt-to-Equity Ratio1.00 Current Ratio0.78 Quick Ratio0.77 Sales & Book Value Annual Sales$8.73 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / BookN/AMiscellaneous Outstanding Shares63,880,000Free FloatN/AMarket Cap$7.03 million OptionableOptionable Beta0.78 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:AKAO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achaogen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achaogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.